Last reviewed 2026-04-19 · How we verify

CHINIOFON

Phase 2 active Small molecule

CHINIOFON is a chiniofon drug. It is currently in Phase 2 development.

CHINIOFON is thought to work by interacting with a specific biological target, but the exact mechanism is not well understood.

CHINIOFON is a small molecule drug in the chiniofon class, but information on its target, approved indications, and commercial status is limited. Its mechanism of action and pharmacokinetic properties are not well-documented. As a result, it is difficult to provide a comprehensive summary of CHINIOFON's characteristics and clinical use. Further research is needed to understand its potential applications and safety profile. Unfortunately, there is not enough information available to provide a detailed summary.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CHINIOFON
Drug class	chiniofon
Target	Catechol O-methyltransferase
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine CHINIOFON as a key that fits into a lock in the body. When it binds to the lock, it can either turn the key (activating a response) or block the key from turning (inhibiting a response). However, the specific lock and key interaction for CHINIOFON is not well-documented.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CHINIOFON CI brief — competitive landscape report
CHINIOFON updates RSS · CI watch RSS

Frequently asked questions about CHINIOFON

What is CHINIOFON?

CHINIOFON is a chiniofon drug.

How does CHINIOFON work?

CHINIOFON is thought to work by interacting with a specific biological target, but the exact mechanism is not well understood.

What drug class is CHINIOFON in?

CHINIOFON belongs to the chiniofon class. See all chiniofon drugs at /class/chiniofon.

What development phase is CHINIOFON in?

CHINIOFON is in Phase 2.

What does CHINIOFON target?

CHINIOFON targets Catechol O-methyltransferase and is a chiniofon.

Drug class: All chiniofon drugs
Target: All drugs targeting Catechol O-methyltransferase
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing